| Literature DB >> 27709883 |
Ewa Surmiak1, Aleksandra Twarda-Clapa2,3, Krzysztof M Zak2,3, Bogdan Musielak1, Marcin D Tomala1, Katarzyna Kubica1, Przemyslaw Grudnik2, Mariusz Madej2,3, Mateusz Jablonski1, Jan Potempa2,3, Justyna Kalinowska-Tluscik1, Alexander Dömling4, Grzegorz Dubin2,3, Tad A Holak1,3.
Abstract
The p53 pathway is inactivated in almost all types of cancer by mutations in the p53 encoding gene or overexpression of the p53 negative regulators, Mdm2 and/or Mdmx. Restoration of the p53 function by inhibition of the p53-Mdm2/Mdmx interaction opens up a prospect for a nongenotoxic anticancer therapy. Here, we present the syntheses, activities, and crystal structures of two novel classes of Mdm2-p53 inhibitors that are based on the 3-pyrrolin-2-one and 2-furanone scaffolds. The structures of the complexes formed by these inhibitors and Mdm2 reveal the dimeric protein molecular organization that has not been observed in the small-molecule/Mdm2 complexes described until now. In particular, the 6-chloroindole group does not occupy the usual Trp-23 pocket of Mdm2 but instead is engaged in dimerization. This entirely unique binding mode of the compounds opens new possibilities for optimization of the Mdm2-p53 interaction inhibitors.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27709883 DOI: 10.1021/acschembio.6b00596
Source DB: PubMed Journal: ACS Chem Biol ISSN: 1554-8929 Impact factor: 5.100